Denali Therapeutics Inc. (DNLI) financial statements and ratios from SEC XBRL: revenue $0.00 (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 142.5% |
| FCF Growth (YoY) | -2.0% |
| Price / Book | 4.78 |
| Price / Sales | 1107.05 |
| FCF Yield | -10.5% |
| Altman Z-Score | 14.85 (safe) |
| Sector P/E (Healthcare) | 21.6 |
DNLI overview · DNLI earnings · DNLI KPIs · DNLI investor relations · DNLI ownership · DNLI peers · DNLI filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.